NSETrading Window29 Sept 2026 · 29 Sept 2026, 11:08 am
Trading Window
Piramal Pharma Limited · PPLPHARMA
✦ AI Summary
Piramal Pharma Limited has informed the Exchange regarding the closure of the trading window for all Designated Persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the half year ending September 30, 2026.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Piramal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
PIRAMALPHARMA_29092026110819_SEIntimationwindowclosure.pdf
View document text
29th September, 2026
BSE Limited National Stock Exchange of India Limited
P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex,
Mumbai- 400 001
Bandra (East), Mumbai – 400 051
BSE scrip code: 543635
NSE symbol: PPLPHARMA
Subject: Intimation of closure of trading window
Dear Sir / Madam,
Pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider
Trading) Regulations, 2015 and in terms of the Company’s Code of Conduct to regulate,
monitor and report trading by Designated Persons (‘the Code’), we wish to inform you that the
Trading Window for dealing in securities of Piramal Pharma Limited shall remain closed for
all Designated Persons and their immediate relatives covered under the Code from Thursday,
October 1, 2026 until 48 hours after declaration of the unaudited financial results of the
Company for the half year ending September 30, 2026.
The date of the Board Meeting to approve the said financial results, shall be communicated in
due course.
Kindly take the above on record.
Thank you.
Yours truly,
For Piramal Pharma Limited
Maneesh Sharma
Company Secretary & Compliance Officer
Piramal Pharma Limited
CIN: L24297MH2020PLC338592
Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India
Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com
www.piramalpharma.com